[Therapy of atopic dermatitis].
Atopic eczema is one of the most common diseases in dermatology. Patients suffer from both the chronic relapsing skin disease and the associated emotional stress. Itching and visible lesions on the face and hands are the most unpleasant features for many often young patients, seriously reducing their quality of life. New therapeutic approaches have changed the management of atopic eczema in recent years. Relatively potent new drugs with fewer side effects than corticosteroids help to control the disease. This review focuses on the basic principles of modern atopic eczema treatment, emphasizing basic emollient therapy and topical therapy with calcineurin inhibitors.
Abels
C
C
Dr. August Wolff GmbH & Co. KG Arzneimittel, Sudbrackstrasse 56, 33611 , Bielefeld. christoph.abels@wolff-arzneimittel.de
Proksch
E
E
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002648:Child; D003131:Combined Modality Therapy; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004643:Emollients / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D011537:Pruritus / Q000523:psychology / Q000628:therapy; D011788:Quality of Life / Q000523:psychology; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014508:Urea / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D065095:Calcineurin Inhibitors; D004643:Emollients; D007166:Immunosuppressive Agents; D007073:Immunoglobulin E; C117268:pimecrolimus; D014508:Urea; D016559:Tacrolimus